Gamida Cell to delist as Highbridge takes full ownership Finances March 29, 2024 [ad_1] Israeli stem cell therapy firm Gamida Cell (Nasdaq: GMDA) has introduced that Highbridge Capital Administration, the corporate’s principal…
